Equity Research Biotechnology

Should You Buy Insmed Incorporated Stock in 2026?

By CirclFi Research Team · · Updated · 2/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Insmed Incorporated (INSM) carries a solid Quality of Company rating of 6.7/10. Trading at $119.92, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 2 CirclFi valuation models project upside for Insmed Incorporated (INSM) at $119.92 — the model consensus leans bearish, with a Quality Score of 6.7/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 2 of 2 models suggest overvaluation — majority bearish
  • Quality Score: 6.7/10 — Moderate — mixed signals
  • Value Trap Risk: 18/100 — Minimal — healthy fundamentals
  • Fair Value Range: $4.35 – $4.83 (11% spread)

Bullish Models

0 / 2

Bearish Models

2 / 2

Quality Score

6.7 /10

Moderate — mixed signals

Value Trap Risk

18 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

2 /13
Active Models

Avg. confidence: 26%

What Is the Investment Case for Insmed Incorporated (INSM) in 2026?

What Is the Bull Case vs the Bear Case for Insmed Incorporated (INSM)?

Bull case versus bear case for Insmed Incorporated (INSM) at $119.92, derived from 2 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $4.35 target (-96.4%)
No active model projects meaningful upside for INSM at $119.92. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $4.35 (-96.4%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: manufacturing scale-up challenges represents a meaningful risk for Insmed Incorporated and its Biotechnology peers.

How Does INSM Compare to Its Biotechnology Peers?

RCUS Arcus Biosciences, I
6.7
FENC Fennec Pharmaceutica
6.7
LEGN Legend Biotech Corpo
6.7
MRKR Marker Therapeutics,
6.7
BCYC Bicycle Therapeutics
6.7
ZLAB Zai Lab Limited
6.7
ATRA Atara Biotherapeutic
5.4
TELO Telomir Pharmaceutic
4.8

Valuation data pages: RCUS · FENC · LEGN · MRKR · BCYC · ZLAB · ATRA · TELO · ALZN · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like INSM on Quality?

Closest companies to INSM’s Quality of Company score of 6.7/10, across all industries.

Which Biotechnology Screens Does INSM Appear In?

Why Do CirclFi’s 2 Models Disagree on INSM?

Spread

11%

Fair Value Range

$4.35 – $4.83

A tight 11% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

FTNN

$4.83 (-96.0%)

Most Bearish

Regime Cross

$4.35 (-96.4%)

What Are the Biggest Risks of Buying INSM Stock?

Bearish Consensus

2/2 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View INSM Data Page →

So Is Insmed Incorporated (INSM) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Insmed Incorporated at $119.92. 2/2 models flag overvaluation, median fair value sits at $4.59 (-96.2%), and the risk-reward profile appears unfavorable. Quality at 6.7/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Insmed Incorporated's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About INSM Stock?

Should I buy INSM stock right now?

Based on CirclFi's multi-model analysis, 0 of 2 models see upside for INSM at $119.92. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Insmed Incorporated?

Key risks include: limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does INSM compare to its competitors?

Among Biotechnology peers, INSM holds a Quality Score of 6.7/10. Comparable companies include RCUS (QOC 6.7), FENC (QOC 6.7), LEGN (QOC 6.7). The relative ranking helps investors identify whether INSM offers better fundamental quality than alternatives in the same sector.

Is INSM a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. INSM's Quality Score of 6.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy INSM at?

CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $4.35 to $4.83. At $119.92, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for INSM.

View INSM Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →